XML 63 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition - Schedule of Revenue by Product (Details) - USD ($)
$ in Millions
3 Months Ended
Apr. 03, 2021
Mar. 28, 2020
Disaggregation of Revenue [Line Items]    
Net sales [1] $ 1,010.0 $ 1,083.3
CSCA    
Disaggregation of Revenue [Line Items]    
Net sales [2] 640.5 700.6
CSCA | Upper respiratory    
Disaggregation of Revenue [Line Items]    
Net sales [2] 114.0 154.6
CSCA | Digestive health    
Disaggregation of Revenue [Line Items]    
Net sales [2] 113.5 106.9
CSCA | Pain and sleep-aids    
Disaggregation of Revenue [Line Items]    
Net sales [2] 92.4 120.4
CSCA | Nutrition    
Disaggregation of Revenue [Line Items]    
Net sales [2] 92.0 102.2
CSCA | Healthy lifestyle    
Disaggregation of Revenue [Line Items]    
Net sales [2] 75.5 85.8
CSCA | Oral self-care    
Disaggregation of Revenue [Line Items]    
Net sales [2] 73.7 55.3
CSCA | Skincare and personal hygiene    
Disaggregation of Revenue [Line Items]    
Net sales [2] 53.3 46.7
CSCA | Vitamins, minerals, and supplements    
Disaggregation of Revenue [Line Items]    
Net sales [2] 7.8 6.4
CSCA | Other CSCA    
Disaggregation of Revenue [Line Items]    
Net sales [2],[3] 18.3 22.3
CSCI    
Disaggregation of Revenue [Line Items]    
Net sales 369.5 382.7
CSCI | Upper respiratory    
Disaggregation of Revenue [Line Items]    
Net sales 42.9 84.1
CSCI | Digestive health    
Disaggregation of Revenue [Line Items]    
Net sales 8.5 6.0
CSCI | Pain and sleep-aids    
Disaggregation of Revenue [Line Items]    
Net sales 49.0 46.8
CSCI | Healthy lifestyle    
Disaggregation of Revenue [Line Items]    
Net sales 50.3 43.6
CSCI | Oral self-care    
Disaggregation of Revenue [Line Items]    
Net sales 25.5 23.2
CSCI | Skincare and personal hygiene    
Disaggregation of Revenue [Line Items]    
Net sales 107.0 94.7
CSCI | Vitamins, minerals, and supplements    
Disaggregation of Revenue [Line Items]    
Net sales 59.0 48.5
CSCI | Other CSCI    
Disaggregation of Revenue [Line Items]    
Net sales [4] $ 27.3 $ 35.8
[1] Derived from the location of the entity that sells to a third party.
[2] Includes net sales from our OTC contract manufacturing business.
[3] Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.
[4] Consists primarily of our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.